QUERCETIN AS A POTENTIAL THERAPEUTIC AGENT IN HYPERTENSION COMPLICATED BY CONNECTIVE TISSUE DYSPLASIA

Authors

DOI:

https://doi.org/10.52914/apmp.v5i2.69

Keywords:

hypertension, diseases of the cardiovascular system, diseases of the circulatory system, quercetin

Abstract

This article summarizes data on the effect of quercetin during the treatment of arterial hypertension, complicated by connective tissue dysplasia. Currently, numerous studies are being conducted to study the role of various genes in the development of arterial hypertension. One of the risk factors for hypertension, which remains insufficiently studied, is collagen pathology - undifferentiated connective tissue dysplasia (UND). The presence of connective tissue in all organs and systems, its common origin with mesenchyme, smooth muscle, blood, and lymph leads to dysplastic changes in any organ and system. Among the many metabolic agents in the treatment of hypertension in combination with DST, the bioflavonoid quercetin, which has a pronounced antioxidant effect, deserves the most attention. The use of water-soluble quercetin in the complex therapy of patients with hypertension in combination with DST reduces the frequency of recurrence of hypertensive crises in the post-hospital period, reduces the number of complications, leads to a decrease in blood stabilization, pressure, additional hypotensive effect.

Author Biography

Volodymyr Pyndus, Lviv Medical University

References

Clinical recommendations on arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) in 2013. Arterial. Hypertension. 2013. No. 4 (30). P. 61-157. URL: https://doi.org/10.1093/eurheartj/eht151 DOI: https://doi.org/10.1093/eurheartj/eht151

Huffman M., Lloyd Jones D., Ning H. et al. Quantifying Options for Reducing Coronary Heart Disease Mortality By 2020. Epidemiology and Prevention. Circulat. 2013. Vol. 127. No. 5. P. 2477-2484. DOI: 10.1161/CIRCULATIONAHA.112.000769 DOI: https://doi.org/10.1161/CIRCULATIONAHA.112.000769

Svishchenko E.P., Mishchenko L.A. Clinical and demographic characteristics of patients with newly detected arterial hypertension: results of the START study. Ukr. cardiol journal. 2017. No. 6. P. 14-23. URL: https://ucardioj.com.ua/index.php/UJC/article/view/97

Tseluiko V.V., Yakovleva L.M. Genetic aspects of arterial hypertension in patients with coronary heart disease. Arterialny hipertensiya. 2013. No. 5(31). URL: http://www.mif-ua.com/archive/article/37263

Babak O.Ya., Andreeva A.O. Hormonal changes in adipose tissue of patients with hypertension and obesity. Ukr. therapist journal . 2013. No. 1. P. 63-67.URL: https://doi.org/10.22141/2224-0721.16.7.2020.219007 DOI: https://doi.org/10.22141/2224-0721.16.7.2020.219007

Williams B., Lacy P., Thom S. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results and the Conduit Artery Function Evaluation (CAFE) study. Circulat. 2006. Vol. 113. P. 1213-1225. DOI: 10.1161/circulationaha.105.595496 DOI: https://doi.org/10.1161/CIRCULATIONAHA.105.595496

Characterization of cardiovascular risk factors in hypertensive patients receiving dual combination antihypertensive drugs: results from the FACTOR-Duo study. Ukrainian Journal of Cardiology. 2024. Vol. 31. Iss. 4. P. 23−34. URL: https://doi.org/10.31928/2664-4479-2024.4.2334. DOI: https://doi.org/10.31928/2664-4479-2024.4.2334

Koval S., Penkova M., Mysnychenko O. Changes in the nature of the disease in patients with hypertension and type 2 diabetes — representatives of the civilian population after a long stay in the combat zone. International journal of endocrinology 2024. Vol.19. No.8. P. 586–591. URL: https://doi.org/10.22141/2224-0721.19.8.2023.1342 DOI: https://doi.org/10.22141/2224-0721.19.8.2023.1342

Whelton A. Hyperuricemia and hypertension. Hypertension. 2012. No.60. P. 1112-1113. URL: https://doi.org/10.1161/HYPERTENSIONAHA.112.198341 DOI: https://doi.org/10.1161/HYPERTENSIONAHA.112.198341

Zaremba E.Kh., Rak N.O., Mushroom N.V. et al. The relationship between undifferentiated connective tissue dysplasia and arterial hypertension. Health and society. 2017. No. 1-2. P. 139-140. URL: https://doi.org/10.22141/2224-0551.12.6.2017.112842 DOI: https://doi.org/10.22141/2224-0551.12.6.2017.112842

Nikolenko V.N, Oganesyan M.V, Vovkogon A.D. et al. Morphological signs of connective tissue dysplasia as predictors of frequent post-exercise musculoskeletal disorders. BMC Musculoskelet Disord. 2020. Vol.8. No.21(1). P.660. DOI: 10.1186/s12891-020-03698-0 DOI: https://doi.org/10.1186/s12891-020-03698-0

Tsubanova N., Kovpak A., Zamorskyi I. Study of possible sex features of ramipril and candesartan treatment under experimental arterial hypertension in rats. Ceska Slov Farm. 2022. Vol.71. No.3. P.116-120. PMID: 36058640 . DOI: https://doi.org/10.5817/CSF2022-3-116

Downloads

Published

02-11-2024

How to Cite

Fedorov, Y., Kovpak, A., Pyndus, V., & Golota, S. (2024). QUERCETIN AS A POTENTIAL THERAPEUTIC AGENT IN HYPERTENSION COMPLICATED BY CONNECTIVE TISSUE DYSPLASIA . Actual Problems of Medicine and Pharmacy, 5(2), 1–6. https://doi.org/10.52914/apmp.v5i2.69